Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.47 |
| ▸ | NOS3 | P29474 | 5/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468369 | 0.82 | ADORA1 (0.46) | NOS2NOS3NOS1LCKMAPK1 | |
| SCHEMBL4504096 | 0.80 | LCK (0.67) | NOS2NOS3LCKMAPK1SMN1; SMN2 | |
| SCHEMBL30711612 | 0.80 | LCK (0.67) | NOS2NOS3LCKMAPK1SMN1; SMN2 | |
| SCHEMBL13983675 | 0.79 | LCK (0.44) | NOS2NOS3NOS1LCK | |
| SCHEMBL4642161 | 0.78 | MEN1 (0.43) | LCKNPC1RAB9AMAPT | |
| SCHEMBL13727358 | 0.77 | LCK (0.46) | LCKMAPK1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL28406968 | 0.75 | CDK8 (0.35) | LCKMAPK1NPC1RAB9AMAPT | |
| SCHEMBL18146934 | 0.75 | FBP1 (0.46) | MAPK1ALDH1A1RAB9ALMNAMAPT | |
| SCHEMBL18299391 | 0.73 | LCK (0.43) | LCKMAPK1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL25222774 | 0.72 | NOS2 (0.50) | NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893609-B1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7462634-B2 | N-(pyridin-2-yl)-sulfonamide derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1893609-A1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070072914-A1 | N-(pyridin-2-yl)-sulfonamide derivatives | AGOURON PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006134467-A1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072914-A1 | N-(pyridin-2-yl)-sulfonamide derivatives | HSD11B1, HSD3B1, HSD11B2 | NOS2 2065/4885NOS3 1952/4885NOS1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.